Cystic fibrosis (CF) is a genetic disease with mutational changes leading to profound
dysbiosis, both pulmonary and intestinal, from a very young age. This dysbiosis plays an …

Patients with cystic fibrosis (CF) are repeatedly exposed to antibiotics, especially during the
pulmonary exacerbations of the disease. However, the available therapeutic strategies are …

The cystic fibrosis (CF) lung microbiome has been studied in children and adults; however,
little is known about its relationship to early disease progression. To better understand the …

Illumina and nanopore sequencing technologies are powerful tools that can be used to
determine the bacterial composition of complex microbial communities. In this study, we …

The introduction of mutation-specific combination therapy with the cystic fibrosis
transmembrane conductance regulator (CFTR) modulators elexacaftor/tezacaftor/ivacaftor …

The past decade has seen significant advances in understanding of the pathogenesis and
progression of lung disease in cystic fibrosis (CF). Pulmonary inflammation, infection, and …

The intestinal microbiota is essential for nutrient acquisition, immune development, and
exclusion of invading pathogens. The upper respiratory tract (URT) microbiota is less well …

The lung harbours a diverse array of microbes whose dynamic composition is influenced by
both host and environmental factors. Thus far, most studies have described the microbial …

Rationale In infants and young children with cystic fibrosis, lower airway infection and
inflammation are associated with adverse respiratory outcomes. However, the role of lower …

Abstract Knowledge of whether and how respiratory microbiota composition can prime the
immune system and provide colonisation resistance, limiting consecutive pathobiont …